26 results
10-K
2023 FY
NMRA
Neumora Therapeutics, Inc. Common Stock
7 Mar 24
Annual report
4:05pm
identity, strength, quality and purity;
potential inspection of selected clinical investigation sites to assess compliance with GCPs; and
FDA review … on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations
8-K
EX-99.1
NMRA
Neumora Therapeutics, Inc. Common Stock
8 Jan 24
Regulation FD Disclosure
8:32am
Human t30 hours 30 – 40 hours Under investigation 1/2 6 *175 µg/kg was the highest dose used to estimate Kappa receptor occupancy in nonhuman
424B4
NMRA
Neumora Therapeutics, Inc. Common Stock
18 Sep 23
Prospectus supplement with pricing info
4:12pm
, including:
the size and nature of the patient population;
the severity of the disease under investigation;
eligibility criteria for the trial … to permit the import or export of products, or require us to conduct a product recall.
Any government investigation of alleged violations of law could
S-1/A
EX-1.1
xj1d f0vdlgl02kinu
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
plh9o zn5
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-10.13
l0fxmafyxkyi
11 Sep 23
IPO registration (amended)
6:07am
S-1
xltnta6iku 6n3lwa
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.3
mssio
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.5
ctf7aw0a plk
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.18
vmc2egca ne0fts2xfbs
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.1
6f0ddtda
25 Aug 23
IPO registration
5:03pm
S-1
EX-2.2
3uswr fyfkkz0ip0g1i5
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.4
hj3c6gav
25 Aug 23
IPO registration
5:03pm
DRS/A
EX-10.19
asm7 dbgjpeo9130
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
oyosw3i2
9 Aug 23
Draft registration statement (amended)
12:00am
DRS/A
qpy6pn 8h
30 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
iy6ax
2 May 23
Draft registration statement (amended)
12:00am
DRS/A
8igvj
2 Sep 22
Draft registration statement (amended)
12:00am